IVF and the new ethics

IVF imposes a distinctive neurobiological burden on the partner undergoing treatment, primarily the woman receiving ovarian stimulation. Supraphysiological hormone levels produced by stimulation protocols alter mood regulation, sleep architecture, and stress reactivity for the duration of the cycle, and for some weeks after. The partner not undergoing treatment experiences a secondary stress response shaped by helplessness, financial anxiety, and the social demand to be supportive in ways that may not match the actual emotional terrain. Pair-bonding neurochemistry, particularly oxytocin and vasopressin systems, is reshaped by the experience of shared adversity: couples who navigate IVF together and emerge with or without a child often report changes in the texture of their bond that they describe in terms of depth rather than ease. The neurobiology of repeated cycles, especially unsuccessful ones, includes patterns consistent with prolonged grief and ambiguous loss — the body and brain process the absence of a child that almost was, repeatedly, without the social rituals that accompany other losses.

The dominant psychological mechanism in IVF is anticipatory regret management. Each decision — number of embryos to create, whether to test, what to test for, when to transfer, when to stop — is taken under the shadow of imagined future regret. Couples who can articulate their regret functions to each other tend to make decisions they can live with. Couples who cannot tend to make decisions that one or both later disavow. A second mechanism is intolerance of uncertainty, which IVF aggravates because the process produces probabilistic outcomes at every stage. Partners with low tolerance for ambiguity often push for more testing, more information, more interventions, sometimes beyond the point where additional data improves decisions. A third mechanism is the diffusion of agency: when treatment proceeds through dozens of clinical steps, partners can lose track of what they actually chose versus what was chosen for them by protocol, and post-hoc the experience can feel imposed rather than authored. Maintaining authorship is psychological work.

IVF interacts with the developmental stage of the partnership in characteristic ways. Younger couples entering treatment for unexplained infertility often experience it as an unexpected detour from a normative developmental trajectory; the work is integrating an unanticipated chapter. Older couples using IVF for age-related fertility decline often experience it as a chosen acceleration of a planning timeline that earlier life choices had stretched; the work is closing the gap. Couples using IVF after cancer treatment, for genetic carrier issues, or for same-sex family formation each face a distinct developmental pattern. Across all of these, the period of active treatment becomes a developmental phase in itself, with its own internal stages: hope, disappointment, decision points, transitions. Couples who recognize the period as a phase tend to plan for life after it — whether the outcome is a child, no child, or some configuration in between — and that planning carries them through.

The cultural treatment of IVF has moved from secrecy in the 1980s to ordinary disclosure in the 2020s. Celebrity announcements, social-media documentation of cycles, and dedicated podcasts have built a public vocabulary. The vocabulary remains uneven across communities. In some religious traditions IVF is fully accepted; in others, particularly traditional Catholic and some Orthodox communities, it is opposed on grounds related to embryo status and the separation of procreation from intercourse. Couples within those traditions navigate a more complex cultural landscape: their treatment decisions are simultaneously medical, marital, and theological. Secular professional-class culture in major American cities now treats IVF as routine, even expected, which produces its own pressure on couples who might otherwise have stopped trying earlier. The cultural script is incomplete in important ways — there is still no widely shared ritual for the disposition of unused embryos, for instance — and partners often improvise.

Couples planning or undergoing IVF benefit from concrete planning practices that the clinical encounter does not always prompt. These include: writing down disposition preferences for unused embryos before the first cycle, not after; agreeing in advance on a stopping rule for unsuccessful cycles, including both number of attempts and financial limits; deciding whether to disclose treatment to family and friends and what to disclose; choosing a clinic based on cumulative live-birth rate per intended parent rather than per-cycle success rate; budgeting for at least two cycles even if planning for one; and securing legal counsel for any donor or surrogacy arrangement before contributions are made. Couples using preimplantation genetic testing benefit from genetic counseling that addresses what the results will and will not tell them and what they would do with various outcomes. Partners who do this work in advance make harder decisions more easily when the decisions arrive.

The relational signature of healthy IVF navigation is shared authorship of decisions, equal distribution of the cognitive and emotional labor, and mutual permission to grieve along the way. The partner not receiving injections still has a role: scheduling, finances, household management, emotional witness. Couples in which the non-injecting partner withdraws into work or hobbies tend to fare worse than those in which both partners stay engaged. Sexual intimacy often becomes complicated during treatment because the link between sex and reproduction has been clinically severed and the body is being managed for fertility rather than pleasure. Couples that explicitly protect non-reproductive intimacy — sexual or otherwise — through the treatment period tend to preserve relational quality. The decision about whether to continue treatment after a loss or a failed cycle is the most consequential relational decision of the process and benefits from being made jointly, slowly, and outside the immediate aftermath of disappointment.

IVF surfaces ancient philosophical questions in new forms. What is the moral status of an early embryo? Does the value of a potential life depend on intent, on development, on relationship, on viability? Is selection against disease meaningfully different from selection for trait? Does separating reproduction from intercourse alter the meaning of either? Different philosophical traditions answer these questions differently, and partnerships within mixed traditions — religious and secular, conservative and progressive — must find working answers that allow shared action. The Catholic natural-law tradition gives one answer; the secular utilitarian frame gives another; care ethics gives a third. None of these is automatically authoritative for a given couple. The work is articulating which frame each partner actually holds and finding the overlap that supports the decisions the couple needs to make. Pretending agreement where there is none generates trouble that arrives later, often when an embryo decision is required.

The first IVF birth was Louise Brown in 1978; the technology is barely two generations old. Its early reception was hostile in many quarters and skeptical in most. The mainstreaming has been rapid: by 2020, roughly two percent of births in the United States were conceived through IVF. The historical arc resembles the earlier arc of contraception, which moved from illegal to ubiquitous over a similar span. Each technology required the construction of an ethical and legal infrastructure that did not exist at its introduction; each generated transitional anxieties that have not fully resolved. Earlier reproductive technologies, including artificial insemination with donor sperm dating back to the late nineteenth century, established some of the legal vocabulary now applied to IVF, particularly around parentage and donor relationships. Historical awareness helps couples see that the unsettled ethical landscape they are navigating is the normal condition for a technology in its first generations, not a sign that they are doing it wrong.

The experience of IVF varies dramatically with insurance coverage, geographic access to clinics, employer benefits, religious community context, and the legal status of embryos in the relevant state. A couple in Massachusetts with comprehensive coverage and access to a top-tier clinic faces a different experience than a couple in Mississippi paying out of pocket and traveling four hours each way. The presence or absence of paid medical leave shapes how the injection and monitoring schedule can be integrated with work. The willingness of extended family to provide childcare during treatment for couples with existing children matters. The political climate, which now includes the possibility of state-level restrictions on embryo creation or storage, adds a parameter that did not exist five years ago. Couples planning IVF need to map their specific contextual factors and adjust the plan accordingly rather than following a generic template.

IVF sits at the intersection of medicine, law, insurance, technology, and family. The clinic is one node; the lab is another; the lawyer is a third; the insurance company a fourth; the employer a fifth; the genetic-testing laboratory a sixth; the cryopreservation facility a seventh. Each has its own information system, its own pace, its own failure modes. Couples that integrate well with this system — by maintaining a single document with all relevant records, by tracking decisions and dates, by knowing which entity to call for which question — operate more effectively. The systemic complexity also means that errors occur: embryos have been mislabeled, transferred to the wrong patient, lost in storage failures. These errors are rare but real, and they have produced some of the most difficult cases in reproductive law. Couples cannot eliminate system risk but can reduce it by selecting clinics with strong quality records and by maintaining their own records as a check on the system.

The integration point is that IVF extends the planning horizon of partnership without changing the underlying work of partnership. Couples that plan well together with the older toolkit also plan well with the new one. Couples that do not, struggle in both eras. What has changed is the cost of poor planning: with IVF, decisions about embryos, donors, and surrogacy create durable obligations that earlier reproductive arrangements did not, and disagreements that surface late in the process are harder to resolve because the facts on the ground are harder to reverse. The new ethics is not a separate ethics; it is the older partnership ethics applied to a wider planning space. Couples that recognize this continuity, rather than treating IVF as a wholly novel ethical realm, tend to make decisions that align with their other commitments and that they can defend to themselves over time.

Several technological developments will reshape this landscape within the next decade. In vitro gametogenesis, the production of eggs and sperm from skin cells, would eliminate the donor requirement for many infertility cases and would enable reproduction between same-sex partners using their own genetic material. Improvements in embryo testing, including more reliable polygenic scoring, will expand the selection menu. Artificial wombs, in early development, could eventually decouple gestation from the human body entirely. Each of these will introduce new ethical clusters and new partnership negotiations. Legal frameworks will lag the technology, as they have throughout the IVF era. Couples in coming decades will face planning decisions that current couples cannot imagine, and the meta-skill — joint deliberation under uncertainty, with technological options that exceed traditional ethical vocabulary — will continue to be the durable capacity. The technology will keep changing. The work of two people deciding together how to use it will not.

Cahn, Naomi. The New Kinship: Constructing Donor-Conceived Families. New York: New York University Press, 2013.

Cahn, Naomi. Test Tube Families: Why the Fertility Market Needs Legal Regulation. New York: New York University Press, 2009.

Cohen, I. Glenn. Patients with Passports: Medical Tourism, Law, and Ethics. New York: Oxford University Press, 2015.

Cohen, I. Glenn, Eli Y. Adashi, Susannah Baruch, and Russell A. Faust, eds. Reproductive Technologies and the Law. New York: Cambridge University Press, 2018.

Daar, Judith. The New Eugenics: Selective Breeding in an Era of Reproductive Technologies. New Haven: Yale University Press, 2017.

Daar, Judith. Reproductive Technologies and the Law. 2nd ed. New Providence, NJ: LexisNexis, 2013.

Greenhouse, Linda. "The Supreme Court's Quiet Reproductive Revolution." New York Times, May 4, 2024.

Kitchener, Caroline. "How an Alabama Court Ruling Could Reshape IVF Nationwide." Washington Post, February 22, 2024.

Markens, Susan. Surrogate Motherhood and the Politics of Reproduction. Berkeley: University of California Press, 2007.

Marty, Robin. The New Handbook for a Post-Roe America. New York: Seven Stories Press, 2021.

Rosenthal, Linda. "Assisted Reproduction and the State." Yale Journal of Law and Feminism 28, no. 2 (2017): 211-258.

Ziegler, Mary. Abortion and the Law in America: Roe v. Wade to the Present. Cambridge: Cambridge University Press, 2020.